Sanara MedTech Inc.
For the period ended Dec 31, 2025. Filed Mar 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 24, 2026
SMTI$32.10+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash | $16,578,857 | $15,878,295 |
| Accounts receivable, net | 11,998,075 | 12,408,819 |
| Accounts receivable – related parties | - | 40,566 |
| Inventory, net | 3,948,748 | 2,753,032 |
| Convertible loan receivable | - | 1,101,478 |
| Prepaid and other assets | 948,620 | 1,022,464 |
| Current assets related to discontinued operations (Note 3) | 67,863 | 101,334 |
| Total current assets | 33,542,163 | 33,305,988 |
| Long-term assets | ||
| Intangible assets, net | 18,640,673 | 23,481,095 |
| Goodwill | 3,601,781 | 3,601,781 |
| Investment in equity securities | 14,626,858 | 6,212,945 |
| Right of use assets – operating leases | 2,075,634 | 1,447,907 |
| Property and equipment, net | 456,962 | 432,317 |
| Long-term assets related to discontinued operations (Note 3) | - | 19,609,959 |
| Total long-term assets | 39,401,908 | 54,786,004 |
| Total assets | $72,944,071 | $88,091,992 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $2,313,761 | $1,499,764 |
| Accounts payable – related parties | 25,000 | 30,913 |
| Accrued bonuses and commissions | 11,781,435 | 10,084,650 |
| Accrued royalties and expenses | 2,684,626 | 2,265,237 |
| Earnout liabilities – current | 235,001 | - |
| Operating lease liabilities – current | 353,229 | 358,687 |
| Current liabilities related to discontinued operations (Note 3) | 1,233,478 | 1,050,820 |
| Total current liabilities | 18,626,530 | 15,290,071 |
| Long-term liabilities | ||
| Long-term debt | 45,970,937 | 30,689,290 |
| Earnout liabilities – long-term | - | 748,001 |
| Operating lease liabilities – long-term | 1,868,703 | 1,237,051 |
| Other long-term liabilities | 548,125 | 1,215,617 |
| Total long-term liabilities | 48,387,765 | 33,889,959 |
| Total liabilities | 67,014,295 | 49,180,030 |
| Commitments and contingencies (Note 10) | - | |
| Shareholders’ equity | ||
| Common Stock: $0.001 par value, 20,000,000 shares authorized; 8,946,913 issued and outstanding as of December 31, 2025 and 8,753,773 issued and outstanding as of December 31, 2024 | 8,948 | 8,754 |
| Additional paid-in capital | 81,232,536 | 77,179,211 |
| Accumulated deficit | (75,303,042) | (37,784,392) |
| Total Sanara MedTech shareholders’ equity | 5,938,442 | 39,403,573 |
| Equity attributable to noncontrolling interest | (8,666) | (491,611) |
| Total shareholders’ equity | 5,929,776 | 38,911,962 |
| Total liabilities and shareholders’ equity | $72,944,071 | $88,091,992 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.